New drug for heart failure: ARB & NEP dual inhibitor LCZ696
Received:April 25, 2016  Revised:May 30, 2016
View Full Text  View/Add Comment  Download reader
DOI:10.11915/j.issn.1671-5403.2016.07.0131
Key words:LCZ696  ARB-NEP dual inhibitor  HF new drug
Author NameAffiliationE-mail
QIAN Fang-Yi Chinese PLA Hospital No. 306, Beijing 100101, China qianfangyibj@163.com 
Hits: 1465
Download times: 1092
Abstract:
      Heart failure (HF) is a serious condition representing the end-stage of myriad of cardiovascular diseases. With high prevalence, HF is one of the major focuses in global prevention and management of chronic cardiovascular diseases. Significant progress has been made in pharmacotherapy of HF in past decades, but chronic HF remains to be associated with substantial morbidity and mortality. The recent approval by the US FDA of LCZ696, the first of a new class of drugs with dual angiotensin receptor blocker(ARB) and neprylisin(NEP) inhibition mechanisms, for the treatment of heart failure with reduced left ventricular ejection fraction(HFrEF), represents a major breakthrough in the development of novel pharmacotherapy for HF. In the landmark PARADIGM HF trial, LCZ696 demonstrated significantly improved morbidity and mortality over enalapril, a standard of care in HFrEF. In this review, we discussed the pharmacology, efficacy and clinical application of this new drug.
Close